Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.
about
Autologous hematopoietic stem cell transplantation following high-dose chemotherapy for non-rhabdomyosarcoma soft tissue sarcomasCervical lymph node diseases in childrenPediatric genitourinary oncologyPediatric solid tumor genomics and developmental pliancyCross-species array comparative genomic hybridization identifies novel oncogenic events in zebrafish and human embryonal rhabdomyosarcomaIdentification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models.Effectiveness of chemotherapy in rhabdomyosarcoma: example of orbital primary.Vinorelbine in previously treated advanced childhood sarcomas: evidence of activity in rhabdomyosarcoma.Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family.A human recombinant autoantibody-based immunotoxin specific for the fetal acetylcholine receptor inhibits rhabdomyosarcoma growth in vitro and in a murine transplantation model.Head and neck sarcomas: the UCLA experience.Primary alveolar rhabdomyosarcoma of the bone: two cases and review of the literatureGene expression profiling for survival prediction in pediatric rhabdomyosarcomas: a report from the children's oncology group.Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children's Oncology GroupPhyseal bystander effects in rhabdomyosarcoma radiotherapy: experiments in a new xenograft model.MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53.Tumor volume and patient weight as predictors of outcome in children with intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group.Aldehyde Dehydrogenase 1 (ALDH1) Is a Potential Marker for Cancer Stem Cells in Embryonal Rhabdomyosarcoma.Clinicopathological characteristics and treatment outcomes of Chinese patients with genitourinary embryonal rhabdomyosarcoma.Proton radiotherapy for solid tumors of childhood.In search of targeted therapies for childhood cancer.Diagnosis, classification, and management of soft tissue sarcomas.The inconvenience of convenience cohorts: rhabdomyosarcoma and the PAX-FOXO1 biomarker.Current chemotherapeutic strategies for rhabdomyosarcoma.Intensity Modulated Radiotherapy (IMRT) and Fractionated Stereotactic Radiotherapy (FSRT) for children with head-and-neck-rhabdomyosarcomaNew drug developments for patients with metastatic soft tissue sarcoma.Clinical results of high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation in children with advanced stage rhabdomyosarcoma.The spectrum of pediatric tumors in infancy, childhood, and adolescence: a comprehensive review with emphasis on special techniques in diagnosis.Pediatric undifferentiated sarcoma of the soft tissues: a clinicopathologic study.The role of radiology in paediatric soft tissue sarcomas.Spindle cell lesions of the adult prostate.Botryoid rhabdomyosarcoma of the biliary tract in children: a unique case report.Two Cases of Adolescents with Paratesticular Rhabdomyosarcoma Inadequately Treated: The Problem of Referral.A case of pediatric paratesticular rhabdomyosarcoma with epididymitisRhabdomyosarcoma of the maxillary gingiva.Milestones in the curability of pediatric cancersMolecular classification of rhabdomyosarcoma--genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology GroupManagement and outcome of 239 adolescent and adult rhabdomyosarcoma patients.Prevalence and clinical impact of anaplasia in childhood rhabdomyosarcoma : a report from the Soft Tissue Sarcoma Committee of the Children's Oncology GroupPAX3-FKHR sensitizes human alveolar rhabdomyosarcoma cells to camptothecin-mediated growth inhibition and apoptosis.
P2860
Q24234049-0B1A8D0F-A38D-46DE-AC55-714D9C0E849DQ26865114-F9BCC68B-9DFD-41E9-93BD-A9B7512634CCQ27007650-5C169AFE-43F6-4374-A8E0-8A1B6059DBC8Q27023560-B8FEBCD7-69E6-435A-A1D9-284806581770Q28536066-59497991-1C6E-4F22-B617-CFEC44FA7768Q30491274-AC0CA4A3-4C12-4273-B9A1-DC35E8ED0620Q33195404-AAB15E50-66A1-4E81-A162-EE682BB09A0AQ33343211-22D20FDB-5086-4188-9FA4-05AF1B6E7B85Q33598764-3413CF21-9A2B-4E98-B1AC-0BFF4D757D62Q33692521-95CB054D-64AC-4B59-82B5-8633C4ED29F5Q34505032-6E52BB25-E2D3-4358-8EE9-7C9E4ADBDCDEQ34542936-55BBC559-8EAE-451B-86E7-C93EE45DDCE0Q34578460-6B2BC5A4-7C40-432C-A3A8-5B4CEA39144AQ34879284-8DDBCB3B-A94E-445B-A1DC-D4167DCFB9C4Q34929490-0ED4D580-6239-4A03-8E75-1E80C717D165Q34999483-E4A28B03-6C01-44D9-A98D-A8427802423FQ35051029-C4425508-9889-4C9C-83D7-462B80715449Q35615455-0F942C5D-A709-40A5-ACB8-BC532E04CC4BQ35762410-669B7F09-7EC4-48A5-A986-656AE79C9335Q35924026-C6FD765C-B68B-48E3-B7A2-E5FC21B26548Q35971733-AAA0448F-A793-4E92-B120-F6E858BCE242Q36019296-E6B8F7F1-044E-493D-9A64-2984C5B4BB86Q36084235-BEC9A222-1A63-403E-B32C-39C5D053767CQ36118405-8BDD016D-68C9-4AD9-8403-2A36BA59D77CQ36141759-F40C0806-B487-4EAF-82EB-1943E7979923Q36157324-A759525D-AA05-4214-94BE-A03694CC822FQ36195677-8AFF1962-468C-4E03-A64F-E85C07EDE38BQ36203806-6ABA51B6-08AC-4AA8-8B55-1489A5435846Q36527676-57DFC851-47AE-43E8-AA48-DEFDF4D005CAQ36627178-CFA281C3-41E5-4FBE-8A21-6B52A535DAF2Q36684899-B2316BA3-73D4-4949-871C-B4D97716A01DQ36687487-A20C8A96-968A-4EF0-9752-2CAD55D227FFQ36753647-51D34278-EEB4-4AA7-85DF-A8A3100FC4B5Q36758121-3D378F9B-122C-4935-BA63-F36EA191CD17Q36924288-32FE4283-D3D2-4F09-A8F3-60384992B9DEQ36925083-C3B5E21F-6F51-4151-A16D-5FE23DDA35C7Q37071890-FC0D8017-5FB1-495D-942C-C37796CE2979Q37236280-1E6D5DA2-496A-424F-8773-E48C36926BEAQ37307376-BF2798B5-4F86-4FCB-8A6B-49CDEB23A341Q37337884-352C086E-F8A9-4A60-BFBB-4CD93D01D1AC
P2860
Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
name
Rhabdomyosarcoma and undiffere ...... roup Rhabdomyosarcoma Study V.
@ast
Rhabdomyosarcoma and undiffere ...... roup Rhabdomyosarcoma Study V.
@en
Rhabdomyosarcoma and undiffere ...... roup Rhabdomyosarcoma Study V.
@nl
type
label
Rhabdomyosarcoma and undiffere ...... roup Rhabdomyosarcoma Study V.
@ast
Rhabdomyosarcoma and undiffere ...... roup Rhabdomyosarcoma Study V.
@en
Rhabdomyosarcoma and undiffere ...... roup Rhabdomyosarcoma Study V.
@nl
prefLabel
Rhabdomyosarcoma and undiffere ...... roup Rhabdomyosarcoma Study V.
@ast
Rhabdomyosarcoma and undiffere ...... roup Rhabdomyosarcoma Study V.
@en
Rhabdomyosarcoma and undiffere ...... roup Rhabdomyosarcoma Study V.
@nl
P2093
P1476
Rhabdomyosarcoma and undiffere ...... roup Rhabdomyosarcoma Study V.
@en
P2093
Anderson JR
Donaldson SS
Qualman SJ
P304
P356
10.1097/00043426-200105000-00008
P577
2001-05-01T00:00:00Z